These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 34623480

  • 1. Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy.
    Miler M, Nikolac Gabaj N, Ćelap I, Grazio S, Tomašić V, Bišćanin A, Mitrović J, Đerek L, Morović-Vergles J, Vrkić N, Štefanović M.
    Rheumatol Int; 2021 Dec; 41(12):2195-2203. PubMed ID: 34623480
    [Abstract] [Full Text] [Related]

  • 2. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.
    Roblin X, Boschetti G, Duru G, Williet N, Deltedesco E, Phelip JM, Peyrin-Biroulet L, Nancey S, Flourié B, Paul S.
    Inflamm Bowel Dis; 2017 Nov; 23(11):2048-2053. PubMed ID: 28945636
    [Abstract] [Full Text] [Related]

  • 3. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
    Pascual-Marmaneu Ó, Belles-Medall MD, Ferrando-Piqueres R, Almela-Notari P, Mendoza-Aguilera M, Álvarez-Martín T.
    Farm Hosp; 2021 Aug 25; 45(5):225-233. PubMed ID: 34806581
    [Abstract] [Full Text] [Related]

  • 4. De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months.
    Little RD, Chu IE, Ward MG, Sparrow MP.
    Dig Dis Sci; 2022 Jan 25; 67(1):259-262. PubMed ID: 33763785
    [Abstract] [Full Text] [Related]

  • 5. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
    Boschetti G, Garnero P, Moussata D, Cuerq C, Préaudat C, Duclaux-Loras R, Mialon A, Drai J, Flourié B, Nancey S.
    Inflamm Bowel Dis; 2015 Feb 25; 21(2):331-6. PubMed ID: 25625487
    [Abstract] [Full Text] [Related]

  • 6. Distinct Association of Serum Vitamin D Concentration with Disease Activity and Trough Levels of Infliximab and Adalimumab during Inflammatory Bowel Disease Treatment.
    Mechie NC, Mavropoulou E, Ellenrieder V, Kunsch S, Cameron S, Amanzada A.
    Digestion; 2020 Feb 25; 101(6):761-770. PubMed ID: 31536991
    [Abstract] [Full Text] [Related]

  • 7. Spacing the Administration Interval of Anti-TNF Agents: A Valid Strategy for Patients with Inflammatory Bowel Disease?
    Torres P, Cañete F, Núñez L, Aguilar A, Mesonero F, Calafat M, Fernández C, Teniente A, Mañosa M, López-Sanromán A, Domènech E.
    Dig Dis Sci; 2020 Jul 25; 65(7):2036-2043. PubMed ID: 31858325
    [Abstract] [Full Text] [Related]

  • 8. A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.
    Varma P, Paul E, Huang C, Headon B, Sparrow MP.
    Intern Med J; 2016 Jul 25; 46(7):798-804. PubMed ID: 26865349
    [Abstract] [Full Text] [Related]

  • 9. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
    Aden K, Rehman A, Waschina S, Pan WH, Walker A, Lucio M, Nunez AM, Bharti R, Zimmerman J, Bethge J, Schulte B, Schulte D, Franke A, Nikolaus S, Schroeder JO, Vandeputte D, Raes J, Szymczak S, Waetzig GH, Zeuner R, Schmitt-Kopplin P, Kaleta C, Schreiber S, Rosenstiel P.
    Gastroenterology; 2019 Nov 25; 157(5):1279-1292.e11. PubMed ID: 31326413
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Biomarkers predicting the effect of anti-TNF treatment in paediatric and adult inflammatory bowel disease.
    Winter DA, de Bruyne P, van der Woude J, Rizopoulos D, de Ridder L, Samsom J, Escher JC.
    J Pediatr Gastroenterol Nutr; 2024 Jul 25; 79(1):62-75. PubMed ID: 38698646
    [Abstract] [Full Text] [Related]

  • 12. Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease.
    Lucas Ramos J, Suárez Ferrer C, Poza Cordón J, Sánchez Azofra M, Rueda García JL, Martin Arranz E, Yebra Carmona J, Andaluz García I, Martín Arranz MD.
    Gastroenterol Hepatol; 2021 May 25; 44(5):337-345. PubMed ID: 33272733
    [Abstract] [Full Text] [Related]

  • 13. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M, Duricova D, Bortlik M, Hruba V, Machkova N, Mitrova K, Malickova K, Lukas M, Lukas M.
    Dig Dis; 2017 May 25; 35(1-2):91-100. PubMed ID: 28147356
    [Abstract] [Full Text] [Related]

  • 14. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, Nissinen M, Rautiainen H, Kuisma J, Kolho KL, Färkkilä M.
    J Crohns Colitis; 2013 Oct 25; 7(9):730-5. PubMed ID: 23182163
    [Abstract] [Full Text] [Related]

  • 15. Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases.
    Grinman AB, de Souza MDGC, Bouskela E, Carvalho ATP, de Souza HSP.
    Medicine (Baltimore); 2020 Mar 25; 99(10):e19359. PubMed ID: 32150077
    [Abstract] [Full Text] [Related]

  • 16. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
    Ungar B, Levy I, Yavne Y, Yavzori M, Picard O, Fudim E, Loebstein R, Chowers Y, Eliakim R, Kopylov U, Ben-Horin S.
    Clin Gastroenterol Hepatol; 2016 Apr 25; 14(4):550-557.e2. PubMed ID: 26538204
    [Abstract] [Full Text] [Related]

  • 17. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
    Narula N, Kainz S, Petritsch W, Haas T, Feichtenschlager T, Novacek G, Eser A, Vogelsang H, Reinisch W, Papay P.
    Aliment Pharmacol Ther; 2016 Jul 25; 44(2):170-80. PubMed ID: 27226407
    [Abstract] [Full Text] [Related]

  • 18. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
    Buurman DJ, Blokzijl T, Festen EAM, Pham BT, Faber KN, Brouwer E, Dijkstra G.
    PLoS One; 2018 Jul 25; 13(12):e0208922. PubMed ID: 30533022
    [Abstract] [Full Text] [Related]

  • 19. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis.
    Klingberg E, Strid H, Ståhl A, Deminger A, Carlsten H, Öhman L, Forsblad-d'Elia H.
    Arthritis Res Ther; 2017 Feb 02; 19(1):21. PubMed ID: 28148281
    [Abstract] [Full Text] [Related]

  • 20. Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease.
    Colman RJ, Rubin DT.
    J Crohns Colitis; 2015 Apr 02; 9(4):312-7. PubMed ID: 25616487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.